Lightpoint Medical


Contact David Tuch
Title CEO/Founder


Today, cancer surgery is frequently unsuccessful. For example, 1 in 4 prostate cancer patients will have cancer left behind after surgery. The high failure rate of cancer surgery is for the simple reason that surgeons do not have any way to detect cancer during surgery. The consequences are enormous including repeat operations, additional post-surgical treatment, worse survival outcomes, and increased healthcare costs.
Lightpoint Medical has developed a groundbreaking intra-operative molecular imaging technology to detect cancer during surgery. The technology is based on a recent discovery that PET imaging agents also emit an optical signal called Cerenkov Luminescence. This discovery has enabled Lightpoint to develop a portable molecular imaging scanner compact enough to be brought into the operating room. The lower cost also makes Lightpoint’s technology ideal for low-resource settings. The technology is applicable across a wide number of major cancer indications including stomach, colorectal, breast, prostate and lung cancer. Real-time detection of cancer during surgery will bring substantial health economic savings by reducing repeat operations, freeing-up operating room capacity, and reducing additional post-surgical treatment.
The company is supported by more than $7M in non-dilutive grant funding, $4M in equity funding led by Oxford Technology, and more than $1M from NHS England. Lightpoint’s lead product LightPath™ will be launched in summer 2015.

Company News

Lightpoint Medical and Telix Pharmaceuticals Announce Strategic Collaboration Agreement

DateAug 23, 2021
Lightpoint Medical, a leading medical device company developing and marketing miniaturized imaging and sensing tools for minimally-invasive and robot-assisted surgery, announced today that it has signed a strategic collaboration agreement with Telix Pharmaceuticals Limited.
Read More →

Lightpoint Medical Announces $8 Million in Funding to Support Commercial Launch of its Robotic Cancer Detection Probe

DateMar 25, 2021
Lightpoint Medical, a medical device company developing miniaturized cancer detection tools for robot-assisted surgery, announced today that it has completed an $8 million financing round.
Read More →

Lightpoint's SENSEI robotic gamma probe gains CE mark for sentinel lymph node detection

DateJan 20, 2021
Lightpoint Medical announced Wednesday that its SENSEI robotic gamma probe received the CE mark for intra-operative detection of sentinel lymph nodes. The company said the approval makes SENSEI the first robotic gamma probe to be commercially available to hospitals in Europe.
Read More →

CROWDFUNDING: The 5 most successful crowdfunding campaigns in 2017

DateJan 6, 2018
2017 was a banner year for crowdfunding campaigns. Here are five of the most successful crowdfunding campaigns last year that you need to know about.

Lightpoint Medical Announces Global License Agreement With the University of Arizona

DateMay 17, 2016
Lightpoint Medical Announces Exclusive Global License Agreement With the University of Arizona to Develop Molecular Imaging Technology. The licensing process was facilitated by Tech Launch Arizona, the office of the UA that commercializes inventions stemming from University research.